Disclosed herein are compositions comprising protein antigens and RNA encoding the same (eg., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and/or overcome immune imprinting in SARS-CoV-2.
The invention relates to methods for treating cancer comprising administering to a subject Compound A having a structure of:, or a pharmaceutically acceptable salt thereof, wherein the subject has been administered a CYP3A inhibitor, and particularly, a CYP3A4 inhibitor.
The present invention relates to a compound of formula I (I), as well as to the compound of formula I for use as a GIPR antagonist in a method of medical treatment, for example for the prevention and/or treatment of type 2 diabetes, obesity and/or weight gain.
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof described herein; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and/or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and/or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
The present disclosure relates to compositions comprising a group B streptococcus (GBS) polysaccharide-protein conjugate and a respiratory syncytial virus (RSV) F protein and/or RNA polynucleotide encoding an antigen derived from RSV The present disclosure further relates to methods and uses of the compositions comprising a GBS polysaccharide-protein conjugate and RSV F protein and/or RNA polynucleotide encoding an antigen derived from RSV for the prevention of a disease or infection associated with GBS and/or RSV.
The present disclosure relates to compounds of formula I and pharmaceutically acceptable salts thereof; to their use in medicine; to pharmaceutical compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of formula (I) are GLP-1R modulators and may be useful in the treatment of metabolic, cardiovascular and other diseases and disorders.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A system and method for personalizing health information content provided to a user. The techniques include obtaining user profile data associated with the user in response to a query submitted by the user. The user profile data includes health data of the user and application use data by the user. The techniques further include expanding the query into a plurality of queries based on the health data of the user, performing semantic searches for the plurality of queries, ranking results from the performed semantic searches, aggregating the results from the performed semantic searches based on the ranking to generate an aggregated health information response, and providing the aggregated health information response to the user.
The present disclosure relates to RNA molecules encoding an EBV polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of infectious mononucleosis, and other diseases associated with EBV infection.
This disclosure relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) disclosed herein, and a monoclonal antibody or an antibody-drug conjugate, optionally in further combination with an endocrine therapy agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.
The present invention relates to a process for preparing a cis-1,2-diaryltetralin derivative, a key chiral intermediate in the synthesis of Compound 1.
C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
C07C 41/18 - Preparation of ethers by reactions not forming ether-oxygen bonds
C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
C07C 43/225 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
C07D 303/23 - Oxiranylmethyl ethers of compounds having one hydroxy group bound to a six-membered aromatic ring, the oxiranylmethyl radical not being further substituted, i.e.
The present disclosure relates to new spiro[2.5]octane compounds of formula I and pharmaceutically acceptable salts thereof; to their use in medicine; to pharmaceutical compositions containing them; to processes for their preparation; and to intermediates used in such processes. The spiro[2.5]octane compounds may be useful in the treatment and amelioration of obesity. Formula (I).
A61P 25/00 - Drugs for disorders of the nervous system
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
13.
PROCESS FOR PREPARING N-(6-((1H-PYRAZOL-1-YL)METHYL)-4-METHOXYBENZO[D]ISOXAZOL- 3-YL)-2-METHOXYBENZENESULFONAMIDE
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The invention provides method of using antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The method of using the antibodies include method of treating disease. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
The present disclosure relates to processes and intermediates that are useful for preparing Compound 1 having the formula Compound 1: or a salt thereof.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
16.
IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE
Clostridioides difficileC. difficileC. difficileC. difficileC. difficile toxoid and an adjuvant, wherein the composition is administered two or three times.
This disclosure pertains to the preparation of bifunctional compounds (e.g., Compound 1), intermediates in the preparation of such compounds, and preparation of such intermediates.
C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
18.
PONSEGROMAB FOR USE IN TREATING CACHEXIA IN CANCER PATIENTS
The invention is directed to methods of treating cancer cachexia or cancer by administering to the patient a GDF15 antibody ponsegromab, and especially while the patient is receiving a systemic chemotherapy.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
19.
COAXIAL MIXING DEVICE FOR NANOPARTICLE PREPARATION AND MANUFACTURING EQUIPMENT INCLUDING SUCH MIXING DEVICE
The invention relates to a coaxial flow device (1) capable of creating comparable microenvironments at various operation scales through the continuous introduction and mixing of nanoparticle precursor solutions for the manufacturing of a dispersion comprising nanoparticles, the device including, coaxially arranged, a first tube (3), an annular second tube (5), a central third tube (7) and a tubular mixing portion (9) arranged downstream of said tubes. According to the invention, the outlet (15) of the annular second tube (5) is formed by a plurality of discrete openings (21) designed to cause formation of the microenvironments. Application to the production of RNA, in particular mRNA, or DNA vaccines.
B01F 25/313 - Injector mixers in conduits or tubes through which the main component flows wherein additional components are introduced in the centre of the conduit
B01F 25/00 - Flow mixersMixers for falling materials, e.g. solid particles
20.
METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH AN ANTI-TL1A ANTIBODY
The present disclosure provides methods and compositions for treating inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC) or Crohn's disease (CD), with a therapeutic dose of an anti-TNF-like ligand 1A (TL1 A) antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
21.
ALUMINUM ADJUVANT NANOPARTICLES, METHODS OF MANUFACTURE, AND USES THEREOF
In one aspect, the present disclosure relates to adjuvant nanoparticles comprising aluminum and/or CpG oligodeoxynucleotides. In particular embodiments, the nanoparticles have an average size of less than about 100 nm. Also provided herein are methods of making the nanoparticles using a microfluidic device.
The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and/or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and/or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 213/68 - One oxygen atom attached in position 4
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
23.
METHOD FOR STERILIZING AND FILLING CONTAINERS FOR PHARMACEUTICAL PRODUCT AND RELATED FILLING SYSTEM
The invention relates to a method for sterilizing containers and filling said containers in sterile conditions with a pharmaceutical product, comprising the steps of: - providing a plurality of internally sterile empty containers (1); - performing a filling cycle, comprising the sequential steps of o introducing a group of empty container(s) (1) into a filling enclosure (55); o sterilizing an external surface of the empty container(s) (1) by application of electron beam radiation emitted by an electron beam emitter (73); o introducing a filling needle (75) into each container body (3) and dispensing pharmaceutical product through the filling needle (75); o extracting the group of filled container(s) (1); - repeating a filling cycle with a subsequent group of empty container(s), The power of the electron beam radiation is modulated during the filling cycle between a maximum value and a minimum value, different from the maximum value and different from zero, whereby a plurality of filling cycles are carried out without switching off the electron beam emitter (73). The invention is also directed to a related filling system.
B65B 55/08 - Sterilising wrappers or receptacles prior to, or during, packaging by irradiation
B65B 55/10 - Sterilising wrappers or receptacles prior to, or during, packaging by liquids or gases
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
An automated smart voice-interactive platform allows users to securely register with a provider and have physical conditions monitored, in place of interacting with a variety of human workers, in a fault tolerant and adaptive manner such that interactions improve with each additional user interaction.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G06T 13/40 - 3D [Three Dimensional] animation of characters, e.g. humans, animals or virtual beings
25.
PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF
Described herein are compounds of Formula (I): I and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
26.
ORAL COMPOSITIONS/FORMULATIONS OF 2-({4-[(2S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYL-1,3-BENZODIOXOL-4-YL]PIPERIDIN-1-YL}METHYL)-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID OR A PHARMACEUTICALLY SALT THEREOF
The invention relates to immediate-release oral pharmaceutical compositions and oral controlled release swellable core technology (SCT) tablets of 2-({4-[(2S)-2-(4-chloro-2- fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid (Compound 1) or a pharmaceutically acceptable salt thereof (e.g. tris salt of Compound 1) and process of making such compositions and tablets. The present invention further relates to methods of using these compositions and tablets once daily for weight management control or for treating, e.g., T2DM, obesity, or overweight.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
27.
IMPROVED METHODS FOR PRODUCING GLYCOCONJUGATES BY REDUCTIVE AMINATION IN APROTIC SOLVENT
The present disclosure relates to media and fermentation methods for polysaccharide production in bacterial cell culture. In one aspect, the disclosure relates to cell culture media comprising potassium phosphate and calcium chloride. In another aspect, the disclosure relates to a method of fermenting bacterial cell culture under pressurized conditions. The media and methods disclosed herein are useful for increasing the polysaccharide production and reducing the lag phase of a bacterial cell culture, i.e., Streptococcus pneumoniae.
The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
This invention relates to methods for selecting patients having prostate cancer for treatment with a PARP inhibitor, such as talazoparib, or a pharmaceutically acceptable salt thereof, and an androgen receptor inhibitor, such as enzalutamide, or a pharmaceutically acceptable salt thereof, comprising: i) determining an ERG gene alteration status, wherein the ERG gene alteration is a TMPRSS2-ERG gene fusion/rearrangement, and/or determining an RB1 gene alteration status, from a biological sample of the prostate cancer from the subject; and ii) selecting patients with the TMPRSS2-ERG gene fusion/rearrangement and/or the RB1 gene alteration for treatment.
The invention relates to polypeptides and RNA molecules encoding an E. coli fimbrial antigen PapG mutant. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the polypeptides, RNA molecules, RNA-LNPs and compositions thereof for the prevention of E.coli infection, including urinary tract infection.
Methods for identifying a subject eligible to receiving a therapeutic amount of a CDK4 inhibitor, predicting whether a subject is sensitive to treatment with a CDK4 inhibitor and methods of treating cancer are disclosed. The methods are based on measurement of mRNA expression, protein expression, and/or activity of cyclin-dependent kinase 6 (CDK6), cyclin E1 (CCNE1), cyclin D1 (CCND1), and/or Androgen Receptor (AR).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
33.
CDK4 INHIBITORS AND COMBINATIONS WITH CDK2 INHIBITORS OR FURTHER AGENTS FOR USE IN THE TREATMENT OF CANCER
This invention relates to therapies for treating cancers in a subject comprising a cyclin dependent kinase 4 (CDK4) inhibitor, and optionally in combination with a CDK2 or an additional anti-tumor agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This invention relates to therapies for treating mantle cell lymphoma comprising a cyclin dependent kinase 4 (CDK4) inhibitor or a pharmaceutically acceptable salt thereof, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and/or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and/or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
E. coliE. coli lipopolysaccharides. In one embodiment, the O-polysaccharide molecules are conjugated to streptococcal C5a peptidase (SCP). In some embodiments, the O-polysaccharide molecules are conjugated to SCR using click chemistry.
This disclosure relates to the novel processes for the synthesis of (1H-pyrazol-5-yl)cyclopentyl carbamate compounds, to novel intermediates useful for the synthesis of (1H-pyrazol-5-yl)cyclopentyl carbamate compounds, and to the synthesis of said intermediates.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
39.
IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF
The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.
The invention relates to a vial for containing a pharmaceutical product comprising - a vial body (3) including a substantially cylindrical wall (7) extending along a main axis (X), a bottom wall (8) closing the cylindrical wall (7) at the bottom end thereof and a neck portion (9) coaxially extending from the cylindrical wall (7) at the upper end thereof; and - a cap assembly (5) attached to the neck portion (9) for sealingly closing the inner volume (24) of the vial body (3). The vial body (3) further includes at the bottom end thereof a flange (33) defining a cavity (35) with a non-cylindrical shape, whereby rotation of the vial (1) about the main axis (X) is prevented when the cavity is matingly engaged by a male connecting piece. The invention is also directed to a filling system suitable for filling such vials in sterile conditions with a pharmaceutical product.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
The present disclosure relates to hMPV F protein mutants, nucleic acids or vectors encoding a hMPV F protein mutant, compositions comprising a hMPV F protein mutant or nucleic acid, and uses of the hMPV F protein mutants, nucleic acids or vectors, and compositions.
Described herein are GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
46.
COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST PEPTIDES
Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
The invention relates to benzodiazepine pyrazolo carboxamidesand pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of invention inhibit the activity RSV N-proteins and may be useful in the treatment, prevention, suppression, and amelioration of viral infections such as RSV.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A system and method for providing a user with information associated with a disease or a condition. The method includes receiving user data associated with the user, receiving a query from the user, wherein the query is associated with the disease or the condition, providing content associated with the disease or the condition in response to the query, wherein the content is based on the user data, wherein the content was generated by a generative machine learning model, and providing secondary services associated with the content, wherein the secondary services comprise at least one of (i) ability to purchase a product associated with the disease or the condition or (ii) scheduling for an appointment with a healthcare provider for the disease or the condition.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
Systems and methods for assisting users in managing migraines or symptoms thereof. The methods can include receiving user data, receiving migraine attack data associated with a migraine suffered by the user, receiving third-party app data associated with the user, and providing content to the user via a device associated with the user based on at least one of the user data, the migraine attack data, the third-party app data, or engagement by the user with the software application, wherein the content assists the user in managing migraines or symptoms thereof.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
50.
CRYSTALLINE FORM OF 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
The invention relates to anhydrous crystalline Form 5 of 2-methoxy-N-{4-methoxy-6-[(1H- pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide (Compound A) and to pharmaceutical compositions comprising anhydrous crystalline Form 5 of Compound A and methods of treatment thereof.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to a novel method of preparing ervogastat with a metal catalyst free process. The invention also relates to novel compounds, intermediates, salts, polymorphs used and prepared by this novel method. Formula (I).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
52.
CRYSTALLINE FORMS OF A MUSCARINIC M4 RECEPTOR MODULATOR AND METHODS OF TREATING DISEASES
Crystalline forms of a muscarinic M4 receptor activator, Compound A, pharmaceutical compositions and combinations comprising those crystalline forms, their use in treating diseases or disorders and methods of producing the crystalline forms. Also provided are pharmaceutical compositions comprising a core comprising Compound A or a pharmaceutically acceptable salt or hydrate thereof, and a coating comprising an opacifier.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
53.
SOLID FORMS OF 6-[4-[[3-(DIFLUOROMETHOXY)-2-PYRIDINYL]OXY]-2-METHYLPHENYL]-1,5-DIMETHYL-2,4(1H, 3H)-PYRIMIDINEDIONE, A
Solid crystalline forms of D1 agonist as-(-)-1,5-dimethyl-6-(2-methyl-4- (3-difluoromethoxy-pyridin-2-yloxy)-phenyl]-1H-pyrimidine-2, 4-dione, as well as methods of making and using the same.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
12344 is H or OH; and, wherein the dashed line may be present or absent, and if present, indicates a double bond Also provided are such compounds in an isolated or crystalline form, pharmaceutical compositions and methods for the treatment of and prevention of various disorders related to ACC, in particular, skin disorders like acne.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
55.
NITROGEN-CONTAINING HETEROARYL COMPOUNDS FOR THE TREATMENT OF CHRONIC DISEASES
The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression, and amelioration of disease(s) such as allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IFF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition. Formula (I): (I).
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
The disclosure provides, among other embodiments, improved bacterial capsular saccharide glycoconjugates, improved methods of producing such glycoconjugates, immunogenic compositions comprising such glycoconjugates, and uses thereof.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Described are compositions and methods for prevention of Lyme disease. Also described are methods for production of an RNA molecule comprising an open reading frame encoding a structural domain polypeptide and an open reading frame encoding an outer surface protein A (OspA) lipoprotein polypeptide, including structural domain polypeptides from an influenza neuraminidase structural domain polypeptide, a PIV5 structural domain polypeptide and a RSV- G structural domain polypeptide.
C12N 15/62 - DNA sequences coding for fusion proteins
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
58.
SOLID FORMS OF A GABAA RECEPTOR MODULATOR AND METHODS OF ITS USE
Solid crystalline forms of GABA a receptor modulator 7-ethyl-4- (4'-(ethylsulfonyl)-6-fluoro-2'-methoxy-[l, I '-bipheny l]-3-yl)-7 H- imidazo[ 4,5-c ]pyridazine, as well as methods of making and using the same. Formula (I).
The present disclosure relates to RNA molecules encoding a Neisseria meningitidis polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of meningococcal disease.
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1,G1, L1, L2, R2, R3, a, and b are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, G1, G2and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.
C07C 219/24 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV) polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
The invention relates to compounds of Formula (I): (I), and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders, and conditions such as cancers.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
64.
COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
Provided are a combination therapy comprising inavolisib, palbociclib and fulvestrant and methods of treating PIC3CA-mutant, hormone receptor positive (HR+) and HER2 negative (HER2-) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib, palbociclib and fulvestrant. The combination therapy produces a statistically significant and clinically meaningful improvement to the patient as compared to administering palbociclib and fulvestrant alone to a comparable patient.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
The present disclosure relates to benzodiazepine compounds and pharmaceutically acceptable salts thereof to their use in medicine; to pharmaceutical compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzodiazepine compounds may be useful in the treatment, prevention, suppression and amelioration of RSV infections.
PFIZER HEALTHCARE IRELAND UNLIMITED COMPANY (Ireland)
Inventor
Blake-Haskins, John Andrew
Finn, Gregory Joseph
Soltantabar, Pooneh
Acosta, Jorge Castellano
Mueller, Patrick
Abstract
Provided herein are methods of treating and/or managing multiple myeloma, which comprise administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione ("Compound A"), or an enantiomer or a mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a bispecific antibody comprising a first binding part binding to B cell maturation antigen (BCMA) and a second binding part binding to cluster of differentiation 3 (CD3).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
68.
SYNTHESIS OF 1,5-ANHYDRO-3-({5-CHLORO-4-[4-FLUORO-2-(2-HYDROXYPROPAN-2-YL)-1-(PROPAN-2-YL)-1H-BENZIMIDAZOL-6-YL]PYRIMIDIN-2-YL}AMINO)-2,3-DIDEOXY-D-THREO-PENTITOL
This disclosure relates novel methods to prepare 1,5-anhydro-3-({5-chloro-4-[4- fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2- yl}amino)-2,3-dideoxy-D-threo-pentitol, and hydrates and stereoisomers thereof, as well as intermediates, including solid forms of the intermediates, useful for the preparation of such compounds and the synthesis of said intermediates.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
Disclosed herein are antibodies, agonist peptides, and dual agonist peptides. Further disclosed herein are antibody conjugates comprising the antibodies, agonist peptides, and/or dual agonist peptides disclosed herein. In some embodiments, the antibodies or antibody conjugates of the invention may be used to treat metabolic diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
70.
A CRYSTALLINE FORM OF 6-FLUORO-3-(2,4,5-TRIFLUORO-3-METHOXYPHENYL)-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID
Described herein are 3-phenylbenzo[b]thiophene carboxylic acid and 3-phenylbenzo[b]furan carboxylic acid derivatives and uses thereof in therapy. A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3- methoxyphenyl)-1-benzothiophene-2-carboxylic acid is also disclosed. The compounds disclosed herein can be used as a branched-chain alpha keto acid dehydrogenase kinase inhibitor or a degrader to treat conditions, for example, diabetes, kidney disease, nonalcoholic steatohepatitis, and heart failure.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (USA)
Inventor
Franklin, Edward Michael
Fennell, Brian Joseph
Stack, Edwina Catherine
Mosyak, Lidia
Apgar, James Reasoner
Chabot, Jeffrey Raymond
Khor, Bernard
Mikita, Thomas Jay
Chaparro-Riggers, Javier Fernando
Abstract
Provided herein are antibodies (including antigen-binding fragments thereof) that specifically bind to MIGIS-alpha, including for example without limitation, bispecific MIGIS-alpha/CD3 antibodies, other related antibodies, related nucleic acids, uses, and associated methods thereof. The disclosure also provides processes for making, preparing, and producing antibodies disclosed herein, including antibodies that bind to one or both of MIGIS-alpha and CD3.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
72.
ORAL CONTROLLED-RELEASE MATRIX FORMULATIONS OF 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID OR A PHARMACEUTICALLY SALT THEREOF
The invention relates to an oral controlled-release matrix formulations of danuglipron or a pharmaceutically acceptable salt thereof (e.g. tris salt of danuglipron) and process of making such formulations. The present invention further relates to tablets having such formulations and methods of using these formulations and/or tablets once daily for weight management control or for treating, e.g., T2DM, obesity, or overweight.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
The invention relates to compounds and immunoconjugates of Formula (IV) and pharmaceutically acceptable salts thereof, to the use of the compounds and immunoconjugates in medicine, to compositions containing the compounds and immunoconjugates; to processes for preparing the compounds and immunoconjugates, and to intermediates used in such processes. The compounds and immunoconjugates of the invention may be useful in the treatment of cancer.
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
74.
METHOD OF FORMING MULTI-SPECIFIC ANTIBODIES FROM HOMODIMER ANTIBODIES AND PHARMACEUTICAL PRODUCT INCLUDING MULTI-SPECIFIC ANTIBODIES THUS OBTAINED
The present invention relates an in-vitro method of forming multi-specific antibodies from first and second homodimer antibodies. The invention also relates to multi-specific antibodies produced from the method.
The application relates to nitrogen-linked benzisoxazole sulfonamide derivatives or pharmaceutically acceptable salts thereof which act as Lysine Acetyl Transferase (KAT) inhibitors useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth, such as cancer, in patients.
C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The invention relates to a method for filling containers in sterile conditions with a pharmaceutical product, comprising the steps of: - supplying a plurality of sterile empty containers (1) into an infeed station, wherein each empty container comprises a cap assembly; - sequentially transferring the empty containers to a filling enclosure (55); - performing a filling cycle, comprising the sequential steps of a) introducing a group of empty container(s) into the filling enclosure (55); b) at least partially closing the filling enclosure (55); c) sterilizing an external surface of the empty container(s) by application of radiation; d) introducing a filling needle (75) through the fixed part (13) of the cap assembly and dispensing a pre-defined amount of pharmaceutical product into each container (1); e) opening the filling enclosure (55) and extracting the group of filled container(s); - repeating a filling cycle with a subsequent group of empty container(s). The invention is also directed to a related filling system.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
B65B 3/04 - Methods of, or means for, filling the material into the containers or receptacles
B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
B65B 31/02 - Filling, closing, or filling and closing, containers in chambers maintained under vacuum or superatmospheric pressure or containing a special atmosphere, e.g. of inert gas
B65B 39/12 - Nozzles, funnels or guides for introducing articles or materials into containers or wrappers movable towards, or away from, container or wrapper during filling or depositing
B65B 43/42 - Feeding or positioning bags, boxes, or cartons in the distended, opened, or set-up stateFeeding preformed rigid containers, e.g. tins, capsules, glass tubes, glasses, to the packaging positionLocating containers or receptacles at the filling positionSupporting containers or receptacles during the filling operation
B65B 43/59 - Means for supporting containers or receptacles during the filling operation vertically movable
B65B 55/02 - Sterilising, e.g. of complete packages
B65B 55/08 - Sterilising wrappers or receptacles prior to, or during, packaging by irradiation
This invention provides methods for producing homogeneous adjuvant formulations comprising a liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) a saponin, and (c) a liposome composition comprising (i) at least one phospholipid selected from 5 phosphatidylcholine (PC) and/or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), distearyl phosphatidylcholine (DSPC), dimyristoyl phosphatidylglycerol (DMPG), dipalmitoyl phosphatidylglycerol (DPPG), distearyl phosphatidylglycerol (DSPG), and a combination thereof, and (ii) cholesterol wherein the mole 0 percent concentration of the cholesterol in the liposome composition is greater than 50% (mol/mol), and further provides the homogeneous adjuvant formulations produced from said methods.
Streptococcus pneumoniaeStreptococcus pneumoniae. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Described are methods, systems, and compositions for continuous production of RNA molecules in a continuous-flow in vitro transcription reaction with immobilized non- consumables. Also described are methods and systems for continuous production of RNA drug substance and RNA drug product from raw materials within an integrated, end-to-end, continuous-flow manufacturing skid.
The invention relates to compounds of Formula (I) (I) wherein Y1a, Y1b, Y2a, Y2b, Y2c, Y2d, Y2e, Y2f, Y2g, Y2hand Y2i are as defined herein and to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful in the treatment of coronavirus infections and coronavirus infection related disorders.
C07D 207/267 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
83.
VEPDEGESTRANT DOSAGE REGIMEN IN CYP3A-INDUCER TREATMENT IN CANCER
The invention relates to a method for treating cancer comprising administering to a subject Compound A having a structure of: or a pharmaceutically acceptable salt thereof, wherein treatment of the Compound A, or the pharmaceutically acceptable salt thereof, is not to be administered with concomitant administration of a CYP3A inducer, and particularly, a CYP3A4 inducer.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure provides compounds that are inducers of KLF2 and pharmaceutical compositions comprising the same. The present disclosure further provides method of treating an inflammatory disease or endothelial dysfunction comprising administering a therapeutically effective amount of the compounds disclosed herein.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
85.
INJECTION DEVICE WITH AN IMPROVED MECHANISM FOR GENERATING AN AUDIBLE FEEDBACK
The invention relates to an injection device comprising a housing (3), an actuation member (20), an injection drive mechanism (25) for driving a plunger (9) within a medicament container (5), the injection drive mechanism including o a plunger rod (31) axially movable for driving the plunger (9); and o an injection compression spring (34) having coils (36) and arranged for biasing the plunger rod (31) to its distal position, the compression spring moving the plunger rod (31) distally as it axially expands. The device (1) further includes a clicking member (38) for generating an audible signal as the injection progresses, said clicking member comprising, fixed within the housing (3), a flexible blade bearing on the coils (36) of the compression spring (34) to produce the audible signal as the compression spring expands.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
The present disclosure describes therapies and uses including an anti-BCMA / anti-CD3 bispecific antibody for the treatment of cancer and/or cancer-associated diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure provides isolated immunogenic polypeptides comprising variant coronavirus spike proteins that are variants of a native coronavirus spike protein or fragment thereof. The present disclosure also provides compositions comprising the isolated immunogenic polypeptides and methods of making and using such compositions.
Compounds are provided having the following structure: or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, Y, m, n, w and x are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a payload, compositions comprising the compounds and methods for their use and preparation are also provided.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, L, X, Y and p are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may modulate the activity of antigens of interest and may be useful in inducing or enhancing an immune response against diseases, disorders and conditions mediated by antigens of interest.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
SOLID FORMS OF (R)-N-(3-(7-METHYL-1H-INDAZOL-5-YL)-1-(4-(1-METHYLPIPERIDIN-4-YL)PIPERAZIN-1-YL)-1-OXOPROPAN-2-YL)-4-(2-OXO-1,2-DIHYDROQUINOLIN-3-YL)PIPERIDINE-1-CARBOXAMIDE
Disclosed herein is a crystalline form of zavegepant, wherein the crystalline form is a crystalline monohydrochloride acetone solvate. Also disclosed herein is an amorphous form of the hydrochloride salt of zavegepant. Methods of making these solid forms as well as pharmaceutical compositions comprising the same are also disclosed.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
This invention relates to high drug loading formulations comprising solid amorphous dispersions of encorafenib, together with one or more surfactants and polymers, and to methods of using such solid forms and pharmaceutical compositions in the treatment of proliferative diseases such as cancer.
Disclosed herein are methods for treating cancer comprising administering to a subject Compound A, or a pharmaceutically acceptable salt thereof, in combination with a selective CDK7 inhibitor.
Provided herein are methods of treatment of cancers, specifically multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies in combination with anti-B cell maturation factor (BCMA)/anti-CD3 bispecific antibodies.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
The present disclosure is directed to solid forms of N-(Methoxycarbonyl)-3-methyl-L- valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-L- prolinamide, I, such as anhydrous forms thereof, an amorphous form thereof, a cyclopentyl methyl ether solvate thereof, an isopropyl acetate solvate thereof, and an ethyl acetate solvate thereof Formula (I) and to pharmaceutical compositions comprising the solid forms and methods of treatment employing the solid forms.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure is directed to processes for preparing N-(Methoxycarbonyl)-3- methyl-L-valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4- (trifluoromethyl)-L-prolinamide, I, and forms thereof such as the Form I polymorph thereof, a cyclopentyl methyl ether solvate thereof, the isopropyl acetate solvate thereof, the ethyl acetate solvate thereof and a mixture of the Form 1 polymorph thereof and microcrystalline cellulose (I) and to compositions comprising the solid forms and to intermediates used to prepare Compound I.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
The invention relates to dosing regimens for the treatment of RSV infection comprising administering to a pediatric subject in need thereof a daily dose of a sisunatovir as a single agent or in combination with other RSV therapies.
The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060 and an endocrine therapy agent.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
Disclosed herein are methods for treating cancer comprising administering to a subject Compound A, or a pharmaceutically acceptable salt thereof, in combination with a selective CDK4 inhibitor.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
patents
